To promote the implementation of innovation-driven development strategy to accelerate the construction of science and technology innovation center of global influence, according to the "Shanghai Science and Technology Innovation" Thirteen Five "plan", Shanghai Science and Technology Commission issued 2017 annual scientific and technological support special projects Guide biomedical field.
First, the scope of collection
Topic I, Biological and Chemical Medicine
Direction 1, pre-clinical research on innovative drugs
Research Objectives: Complete preclinical studies based on new drug candidate compounds with novel structures or mechanisms of action.
Research content: For the preliminary research, it is found that there are new drug candidate compounds with further research and development value, and preclinical research on preparation process, quality standard, efficacy and safety evaluation.
Execution period: completed by June 30, 2020.
The amount of funds: each project does not exceed 700,000 yuan.
Assessment indicators: Complete preclinical studies and obtain clinical trial application acceptance number.
The main body of the application: The enterprises and institutions in this Municipality have applied for invention patents for candidate compounds.
Direction 2, innovative drug clinical research
Research goal: Complete the clinical trial of new drugs, enter the next phase of clinical trials or declare new drug certificates.
Research content: Carry out clinical trials of each phase in response to the clinical approval requirements for new drugs that have been obtained.
Execution period: completed by June 30, 2020.
Funding quota: clinical trial research project, the phase I clinical trial does not exceed 700,000 yuan per project, the phase II clinical trial does not exceed 1 million yuan per project, and the phase III clinical trial does not exceed 2.5 million yuan per project.
Assessment indicators: Complete the current clinical trial and obtain a clinical summary report, or obtain a new drug certificate declaration acceptance number.
The main body of the application: the enterprises and institutions in this city. If the enterprise intends to declare the product, if it has signed a cooperation agreement or a transfer agreement with the production enterprise, it shall be declared by the enterprise; if there is no cooperation agreement or transfer agreement with the production enterprise, it shall have a supporting fund certificate.
Topic II, Modern Chinese Medicine
Direction 1, pre-clinical research on new Chinese medicine
Research goal: To complete preclinical research on new Chinese medicines.
Research content: Preclinical research on preparation process, quality standard, efficacy and safety evaluation for traditional Chinese medicine in-house preparations with clear clinical efficacy or multi-component and multi-target components with certain research basis.
Implementation deadline: completed by September 30, 2020.
The amount of funds: each item does not exceed 700,000 yuan.
Assessment indicators: Complete preclinical studies and obtain clinical trial application acceptance number.
The main body of the application: the enterprises and institutions in this city.
Direction 2, clinical research of new Chinese medicine
Research goal: Complete the clinical trial of new drugs, enter the next phase of clinical trials or declare new drug certificates.
Research content: Carry out clinical trials of various phases in response to the clinical approval requirements for new Chinese medicines that have been obtained.
Implementation deadline: completed by September 30, 2020.
Funding quota: clinical trial research project, the phase I clinical trial does not exceed 700,000 yuan per project, the phase II clinical trial does not exceed 1 million yuan per project, and the phase III clinical trial does not exceed 2.5 million yuan per project.
Assessment indicators: Complete the current clinical trial and obtain a clinical summary report, or obtain a new drug certificate declaration acceptance number.
The main body of the application: the enterprises and institutions in this city. If the enterprise intends to declare the product, if it has signed a cooperation agreement or a transfer agreement with the production enterprise, it shall be declared by the enterprise; if there is no cooperation agreement or transfer agreement with the production enterprise, it shall have a supporting fund certificate.
We are a reliable manufacturers of Cosmetic Raw Materials in China; with advanced R & D and manufacturing in Skin Care Materials. With high-quality products of Cosmetic Ingredients, we can be a trust suppliers / factory. As a wholesale of Daily Chemical Material, we have the perfect after-sales service and technical support. Look forward to your cooperation!
Cosmetic Ingredients,Sialic Acid,Ceramide Powder,Rhodiola Rosea Extract,Daily chemical Material
Xi'an Quanao Biotech Co., Ltd. , https://www.quanaobiotech.com